Krka DDFRA:KN8 -3.02%66 PB Ratio is 3.16 as of Jul. 13, 2026, which is 111% above its 10-year median of 1.50. GuruFocus rates FRA:KN8 with a GF Score™ of 66/100 and a GF Value™ of €148.68 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 924 Drug Manufacturers companies, Krka DD ranks worse than 70.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-13), Krka DD's share price is €257.00. Krka DD's Book Value per Share for the quarter that ended in Mar. 2026 was €81.26. Hence, Krka DD's PB Ratio of today is 3.16.
Warning Sign:
Krka DD stock PB Ratio (=3.21) is close to 10-year high of 3.22.
The historical rank and industry rank for Krka DD's PB Ratio or its related term are showing as below:
FRA:KN8'
s PB Ratio Range Over the Past 10 Years
Min: 1.11 Med: 1.5 Max: 3.22
Current: 3.21
During the past 13 years, Krka DD's highest PB Ratio was 3.22. The lowest was 1.11. And the median was 1.50.
FRA:KN8's PB Ratio is ranked worse than 70.35% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs FRA:KN8: 3.21
During the past 12 months, Krka DD's average Book Value Per Share Growth Rate was 3.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Krka DD was 9.20% per year. The lowest was 3.30% per year. And the median was 5.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Krka DD PB Ratio Related Terms
Krka DD PB Ratio Historical Data
* Premium members only.
The historical data trend for Krka DD's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's PB Ratio distribution charts can be found below:
* The bar in red indicates where Krka DD's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Krka DD's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Krka DD (FRA:KN8) has a PB Ratio of 3.16 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Krka DD and its competitors. This is 111% above median its historical median of 1.50. Over the past decade, Krka DD's PB Ratio has ranged from 1.11 to 3.22. According to the industry distribution chart, Krka DD ranks #650 out of 924 companies in the Drug Manufacturers industry, placing it in the top 70.3%.
Is Krka DD's PB Ratio too high?
Krka DD's current PB Ratio of 3.16 is 111% above median its 10-year median of 1.50. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 3.22. The Drug Manufacturers industry median PB Ratio is 1.91. Krka DD's value of 3.16 is 65.4% above this industry median. Based on the distribution chart, Krka DD ranks #650 out of 924 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Krka DD has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #650 out of 924 companies for PB Ratio. This places Krka DD in the lower half of its industry. The industry median PB Ratio is 1.91. Krka DD's value of 3.16 is 65.4% above this benchmark. Historically, Krka DD's own PB Ratio has ranged from 1.11 to 3.22 over the past decade. While the company's 10-year median is 1.50 vs. the industry median of 1.91, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current PB Ratio of 3.16 is 65.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current PB Ratio is 3.16, which is 111% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.68, compared to a current price of €257.00 — trading 72.9% above its estimated fair value. The current PB Ratio is 3.16, which is 111% above median its 10-year median of 1.50 and 65.4% above the Drug Manufacturers industry median of 1.91. Krka DD's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current PB Ratio is 3.16 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €257.00 is trading 72.9% above its estimated GF Value™ of €148.68.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
PB Ratio: 3.16 (111% above median its 10-year median of 1.50)
GF Value™: €148.68 vs. price of €257.00 (72.9% above fair value)
Industry Position: 65.4% above the Drug Manufacturers median (#650 of 924)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
66GF Score
Get the complete analysis for FRA:KN8
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
